Zacks Investment Management bought a new stake in Omnicell, Inc. (NASDAQ:OMCL - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 28,246 shares of the company's stock, valued at approximately $1,257,000. Zacks Investment Management owned approximately 0.06% of Omnicell as of its most recent filing with the Securities & Exchange Commission.
A number of other institutional investors and hedge funds have also recently modified their holdings of OMCL. Sumitomo Mitsui Trust Group Inc. grew its holdings in shares of Omnicell by 93.3% in the fourth quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,450,416 shares of the company's stock valued at $64,573,000 after purchasing an additional 699,925 shares in the last quarter. Victory Capital Management Inc. grew its holdings in shares of Omnicell by 32.9% in the fourth quarter. Victory Capital Management Inc. now owns 1,526,309 shares of the company's stock valued at $67,951,000 after purchasing an additional 377,883 shares in the last quarter. Renaissance Technologies LLC lifted its position in shares of Omnicell by 79.3% during the fourth quarter. Renaissance Technologies LLC now owns 456,343 shares of the company's stock worth $20,316,000 after purchasing an additional 201,831 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. lifted its position in shares of Omnicell by 46.1% during the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 429,687 shares of the company's stock worth $19,130,000 after purchasing an additional 135,650 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership bought a new stake in shares of Omnicell during the fourth quarter worth $5,372,000. 97.70% of the stock is owned by hedge funds and other institutional investors.
Omnicell Stock Up 1.6 %
Shares of NASDAQ:OMCL traded up $0.50 during trading on Thursday, reaching $31.19. The stock had a trading volume of 152,862 shares, compared to its average volume of 524,145. Omnicell, Inc. has a one year low of $25.12 and a one year high of $55.74. The firm's 50-day simple moving average is $34.67 and its 200 day simple moving average is $41.03. The company has a current ratio of 1.37, a quick ratio of 1.22 and a debt-to-equity ratio of 0.13. The company has a market capitalization of $1.46 billion, a P/E ratio of 115.50, a PEG ratio of 7.53 and a beta of 0.78.
Omnicell (NASDAQ:OMCL - Get Free Report) last issued its quarterly earnings results on Thursday, February 6th. The company reported $0.45 earnings per share for the quarter, missing analysts' consensus estimates of $0.57 by ($0.12). Omnicell had a return on equity of 3.82% and a net margin of 1.13%. As a group, research analysts expect that Omnicell, Inc. will post 1.09 EPS for the current fiscal year.
Analysts Set New Price Targets
A number of analysts recently issued reports on the company. StockNews.com upgraded Omnicell from a "hold" rating to a "buy" rating in a report on Tuesday, April 15th. Benchmark restated a "buy" rating and set a $62.00 price target on shares of Omnicell in a research note on Tuesday, February 4th. Bank of America lowered their price objective on shares of Omnicell from $54.00 to $46.00 and set a "neutral" rating for the company in a research note on Monday, January 6th. JPMorgan Chase & Co. cut their target price on shares of Omnicell from $44.00 to $36.00 and set a "neutral" rating on the stock in a research report on Thursday, March 20th. Finally, Wells Fargo & Company lowered their price target on shares of Omnicell from $40.00 to $38.00 and set an "equal weight" rating for the company in a research report on Thursday, April 17th. Four analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Hold" and an average target price of $50.67.
Read Our Latest Stock Report on OMCL
About Omnicell
(
Free Report)
Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.
Read More
Before you consider Omnicell, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Omnicell wasn't on the list.
While Omnicell currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
